Market research
NOX.AU Noxopharm Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- Not available
- Beta
- 0.13
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000NOX9
- Market cap
- 15M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- Not available
- Beta
- 0.13
About
About Noxopharm Limited
Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment. It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CRO-67, a dual-cell preclinical drug candidate for the treatment of pancreatic cancer. In addition, the company intends to improve mRNA vaccines. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.
Research context
Noxopharm Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NOX.AU discussion.
5 years, 6 months ago
Noxopharm Limited is currently in a long term uptrend where the price is trading 4.8% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Noxopharm Limited's total revenue sank by 65.4% to $1M since the same quarter in the previous year.
Its net income has increased by 3.3% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 7.1% to $-3M since the same quarter in the previous year.
Based on the above factors, Noxopharm Limited gets an overall score of 3/5.